Key takeaways
- 2,500–4,000 US HAE patients meeting prophylaxis criteria (≥3 attacks/yr) but never treated — the primary pre-launch growth market
- 69% vs 44% Donidalorsen (ZENITH-1) vs berotralstat (APeX-2) attack-rate reduction — the oral efficacy bar shifting before a new entrant can launch
- ~$95K/yr Berotralstat WAC — ICER's 2021 fair-value benchmark for HAE prophylaxis; pricing at or below this level is the stronger cost-effectiveness position
- ~1,000–1,500 US patients with FXII-HAE or other normal-C1-INH variants — a structurally underserved subpopulation across all current agents
The binding constraint: grow the never-prophylaxed cohort, not switch stable lanadelumab patients, before donidalorsen's 69% attack-reduction data resets the oral bar.
Lanadelumab (Takhzyro) holds roughly 45% of US HAE prophylaxis share with high KOL loyalty and very low breakthrough-attack rates in stable patients — a population that is structurally hard to switch. Berotralstat (Orladeyo), the once-daily oral entrant, has instead grown the market by converting never-prophylaxed patients, reaching ~20% share since 2020. Of the ~8,000-9,000 US HAE patients, only 35-40% currently receive any prophylaxis; an estimated 2,500-4,000 patients meet prophylaxis criteria (≥3 attacks/year or a laryngeal history) but remain untreated. This gap, not the stable lanadelumab base, is where a new entrant should aim.
The competitive clock is running: donidalorsen, KalVista's oral plasma-kallikrein inhibitor, reported a 69% attack-rate reduction in ZENITH-1 versus berotralstat's 44% in APeX-2, with an FDA submission in 2024 and possible US approval by 2025. Any new pre-launch entrant now competes not just against the two approved agents but against a pipeline drug likely to reset the oral efficacy bar before launch. A distinct commercial niche, the ~1,000-1,500 US patients with FXII-HAE or other normal-C1-INH variants who may respond less well to standard kallikrein-targeted prophylaxis, remains structurally underserved by all three.
Payer posture is precedent-driven: prior-authorisation criteria (confirmed Type 1/2 diagnosis, ≥3 attacks/year or laryngeal history, specialist sign-off) are already established by lanadelumab and berotralstat, and a new entrant's PA will largely mirror them absent a distinct eligibility population. ICER's 2021 berotralstat assessment set a fair-value benchmark close to berotralstat's ~$95,000/year WAC — pricing near or below that level, rather than toward lanadelumab's ~$450,000/year, produces the stronger cost-effectiveness position. Pre-launch priorities: quantify the never-prophylaxed cohort at the 40-80 HAE Alliance member centres, build attack-frequency and laryngeal-history identification tools ahead of launch, and decide specialty-pharmacy and copay-assistance architecture before donidalorsen's approval compresses the window.
Current HAE prophylaxis standard of care — US, 2024
| Drug (Brand / INN) | Mechanism | US Share | WAC | Positioning | Payer PA Posture |
|---|---|---|---|---|---|
| Takhzyro (lanadelumab) | SC mAb prophylaxis q2-4w | ~45% US prophylaxis share | ~$450,000/yr WAC | Dominant switch-resistant incumbent | Established PA criteria (Type 1/2, ≥3 attacks or laryngeal history) |
| Orladeyo (berotralstat) | Oral once-daily prophylaxis | ~20% US prophylaxis share | ~$95,000/yr WAC | Growth via never-prophylaxed patients | Mirrors lanadelumab PA; ICER 2021 fair-value benchmark |
| Donidalorsen (KalVista, pipeline) | Oral plasma kallikrein inhibitor | Pre-FDA (NDA 2024; approval ~2025) | Not yet set | 69% attack-rate reduction (ZENITH-1) — resets oral efficacy bar | Not yet established |
Sources: BioCryst investor day 2023; US HAE Association member survey 2023; Takeda HAE market research; KalVista donidalorsen NDA / ZENITH-1 ClinicalTrials.gov results 2024; ICER berotralstat HAE value assessment 2021; UHC medical policy HAE prophylaxis 2024.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Should a new HAE prophylaxis agent target never-prophylaxed patients or stable lanadelumab switches, and what does berotralstat's commercial history say about which strategy works? • Never-prophylaxed cohort sizing and identification approach • switch-trigger analysis for lanadelumab-stable patients • berotralstat's market-growth mechanism as the commercial analogue
- How does donidalorsen's pipeline data change the oral efficacy bar, and what does that mean for launch timing and clinical positioning? • ZENITH-1 vs APeX-2 comparative efficacy read • NDA/approval timeline risk • positioning options if donidalorsen approves first
- What PA criteria and value benchmark should a new HAE entrant plan against, and what access architecture is required at launch? • PA criteria precedent from lanadelumab/berotralstat • ICER berotralstat fair-value analogue • specialty pharmacy and copay-assistance design requirements
What's inside
-
1 · The Binding Constraint 2 pp
- Never-prophylaxed growth vs switching from stable lanadelumab therapy
- Pressure-tested against donidalorsen's incoming efficacy data
-
2 · Standard-of-Care Landscape & Entrenchment 5 pp
- Lanadelumab's prophylaxis incumbency and switching inertia
- Berotralstat's oral never-prophylaxed growth model
- Donidalorsen pipeline threat (ZENITH-1 69% reduction, NDA 2024)
-
3 · Target Population & Unmet Need 5 pp
- Never-prophylaxed cohort sizing (2,500-4,000 patients)
- FXII-HAE and normal-C1-INH variant subpopulation (~1,000-1,500)
- Attack-cascade biology and identification criteria for physician education
-
4 · Anticipated Payer & Access Posture 5 pp
- PA criteria precedent from lanadelumab/berotralstat
- ICER 2021 berotralstat fair-value benchmark (~$95K/yr)
- Specialty pharmacy and copay-assistance architecture
-
5 · The Assumption Register 2 pp
- Every population, share, and pricing figure sourced and confidence-rated
- Built to survive an internal challenge meeting
-
6 · KOL & Centre Readiness 3 pp
- 80-100 US HAE KOLs at 40-80 HAE Alliance member centres
- Pre-launch engagement sequencing
- Prophylaxis-adoption decision framework by physician type
-
7 · Client Alignment Questions 2 pp
- Open decisions on positioning vs donidalorsen and pricing tier
- Structured for an advisory board or internal alignment session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers HAE launch-readiness intelligence built for pre-launch commercial, medical affairs, and market access teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your asset, target population, and pre-launch question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and access-architecture assumptions.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment synthesises three independent research angles (competitive positioning, target-population epidemiology, and anticipated payer posture) into one integrated pre-launch view. Every figure is drawn from the named primary source in the underlying research base and cross-checked before inclusion; no figure is carried from model memory.
HAE launch-readiness sources: US HAE Association member survey 2023; BioCryst investor day 2023 and berotralstat launch market analysis 2021-2023; Takeda HAE market research; Maurer M et al., WAO HAE guidelines 2022; Cicardi M et al., Allergy 2012; Magerl M et al., Allergy 2019 (HAE variant types); KalVista donidalorsen NDA / ZENITH-1 ClinicalTrials.gov results 2024; ICER berotralstat HAE value assessment 2021; UHC medical policy HAE prophylaxis 2024; Cigna PA berotralstat 2024; Express Scripts HAE formulary.
- Drug approval dates and mechanism claims verified against FDA approval records referenced in the source research base
- Clinical trial results (HELP, APeX-2, ZENITH-1) verified against the named primary publications in the source research base
- Payer PA-criteria language cross-checked against named payer formulary/policy sources (UHC, Cigna, Express Scripts) in the source research base
- Anticipated payer posture is explicitly flagged as anticipated, not confirmed policy, and separated from verified clinical/regulatory facts
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned Launch Readiness assessment includes a 24-30 page PDF covering the binding constraint, SoC entrenchment, target-population sizing, and anticipated payer posture; an editable Excel population-sizing and access-scenario model; and a 12-15 slide PowerPoint readout. A 45-minute analyst call is included with delivery.
Sources How are figures verified for a pre-launch assessment?
Every figure is cited to a live source at the point of writing and cross-checked in an independent audit pass: patient-association member survey data, manufacturer launch and investor disclosures, and international HAE guideline and prevalence literature. Anticipated payer posture is explicitly distinguished from confirmed policy throughout.
Customisation Can I tailor scope to my specific asset or target population?
Yes. The intake form captures your asset's mechanism, target patient segment, and the specific pre-launch question you need answered — a scoping call confirms comparators and access-architecture assumptions before research begins.